🇺🇸 FDA
Pipeline program

JDB0131

JDB-131-201

Phase 2 small_molecule active

Quick answer

JDB0131 for Drug-resistant Tuberculosis is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Drug-resistant Tuberculosis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials